Pharmaxis to progress myelofibrosis drug to Phase II following positive results
30th
Apr 20
Release Date: 30/04/2020 10:50am
Gary Phillips tells Proactive's Andrew Scott they're progressing to a phase II study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF). The move comes on the back of positive results from its phase 1b trial and long-term toxicity studies.
Categories: Video Content